Form 4: Ginkgo Bioworks CFO Mark Dmytruk Reports Stock Transactions

Ginkgo Bioworks CFO Mark Dmytruk reports acquisition and disposal of Class A Common Stock and Restricted Stock Units, including sales to cover tax obligations.

Summary

• On April 1, 2024, Mark Dmytruk, CFO of Ginkgo Bioworks Holdings, Inc., acquired Class A Common Stock through the vesting of Restricted Stock Units (RSUs).
• Specifically, 65,448, 18,125, and 22,916 shares were acquired through RSU vesting on this date.
• Dmytruk also acquired 1,634 shares through the conversion of Class B Common Stock to Class A Common Stock on April 1, 2024.
• On April 2, 2024, Dmytruk disposed of 51,169 shares of Class A Common Stock at a price of $1.05 per share.
• These sales were to cover tax withholding obligations related to the vesting of restricted stock and/or restricted stock units and do not represent discretionary trades.
• Following these transactions, Dmytruk directly owns 865,079 shares of Class A Common Stock.
• Dmytruk also holds 712,436, 634,375, 1,077,084 and 628,685 Restricted Stock Units.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The filing primarily reflects routine transactions related to stock vesting and tax obligations. There's no indication of unusual or concerning activity.

Positives

• The vesting of RSUs indicates that Dmytruk is meeting performance or time-based milestones set by the company.

Negatives

• The sale of shares, even to cover tax obligations, could be perceived negatively by some investors, although it's a common practice.

Risks

• Sales of shares by company executives, even for tax purposes, can sometimes create short-term downward pressure on the stock price.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Investors often monitor these filings to gauge management's sentiment and confidence in the company's prospects.

Comparison to Industry Standards

• Monitoring insider transactions is a common practice in the financial industry.
• Comparing the frequency and size of insider transactions at Ginkgo Bioworks to those of its peers (e.g., Amyris, Zymergen (now Ginkgo Bioworks), Twist Bioscience) can provide insights into relative valuation and management confidence.
• However, direct comparisons can be challenging due to differences in compensation structures and individual financial circumstances.

Stakeholder Impact

• The transactions themselves have a minimal direct impact on stakeholders.
• However, transparency in insider trading activity is important for maintaining investor confidence.

Key Dates